Venus Remedies secures marketing authorizations for Docetaxel, Gemcitabine in Europe

12 Jan 2024 Evaluate

Venus Remedies has secured new marketing authorizations for Docetaxel in concentrations of 160MG/8ML, 20MG/1 ML and 80MG/4ML (Single Vial), as well as Gemcitabine 1G from Malta, Europe. These approvals signify its commitment to expanding its pharmaceutical portfolio and market presence.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

784.80 7.30 (0.94%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×